The University of Chicago Header Logo

Connection

Olufunmilayo Olopade to Risk Assessment

This is a "connection" page, showing publications Olufunmilayo Olopade has written about Risk Assessment.
Connection Strength

1.478
  1. Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol. 2010 Feb; 194(2):309-10.
    View in: PubMed
    Score: 0.210
  2. Correlates of depressive symptoms among women seeking cancer genetic counseling and risk assessment at a high-risk cancer clinic. J Genet Couns. 2006 Aug; 15(4):267-76.
    View in: PubMed
    Score: 0.165
  3. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat Commun. 2021 11 26; 12(1):6946.
    View in: PubMed
    Score: 0.119
  4. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan. JAMA Netw Open. 2019 08 02; 2(8):e1910142.
    View in: PubMed
    Score: 0.101
  5. Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Res Treat. 2010 Nov; 124(2):573-7.
    View in: PubMed
    Score: 0.054
  6. Estrogen deprivation therapy and colon cancer risk in breast cancer patients. Breast J. 2010 Jan-Feb; 16(1):110-2.
    View in: PubMed
    Score: 0.052
  7. Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. J Genet Couns. 2008 Aug; 17(4):365-72.
    View in: PubMed
    Score: 0.047
  8. Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment. J Digit Imaging. 2008 Jun; 21(2):145-52.
    View in: PubMed
    Score: 0.045
  9. Genetic testing in diverse populations: are researchers doing enough to get out the correct message? JAMA. 2007 Dec 26; 298(24):2910-1.
    View in: PubMed
    Score: 0.045
  10. Genetic susceptibility to breast cancer. Rev Endocr Metab Disord. 2007 Sep; 8(3):255-67.
    View in: PubMed
    Score: 0.044
  11. Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol. 2007 May; 14(5):513-21.
    View in: PubMed
    Score: 0.043
  12. Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol. 2006 May 10; 24(14):2197-203.
    View in: PubMed
    Score: 0.041
  13. Confronting genetic testing disparities: knowledge is power. JAMA. 2005 Apr 13; 293(14):1783-5.
    View in: PubMed
    Score: 0.038
  14. Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations. Breast J. 2004 Jan-Feb; 10 Suppl 1:S5-9.
    View in: PubMed
    Score: 0.034
  15. Direct-to-consumer marketing of genetic tests for cancer: buyer beware. J Clin Oncol. 2003 Sep 01; 21(17):3191-3.
    View in: PubMed
    Score: 0.033
  16. The impact of site-specific digital histology signatures on deep learning model accuracy and bias. Nat Commun. 2021 07 20; 12(1):4423.
    View in: PubMed
    Score: 0.029
  17. Cancer genetics in oncology practice. Ann Oncol. 2001 Jul; 12(7):895-908.
    View in: PubMed
    Score: 0.029
  18. Predisposition testing for inherited breast cancer. Oncology (Williston Park). 1998 Aug; 12(8):1227-41; discussion 1241-2.
    View in: PubMed
    Score: 0.024
  19. Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2018 Jun; 169(3):561-571.
    View in: PubMed
    Score: 0.023
  20. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017 11 02; 551(7678):92-94.
    View in: PubMed
    Score: 0.022
  21. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.022
  22. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol. 2017 Jul 10; 35(20):2240-2250.
    View in: PubMed
    Score: 0.022
  23. Genetic testing of families with hereditary diseases. JAMA. 1996 Oct 09; 276(14):1138-9; author reply 1140.
    View in: PubMed
    Score: 0.021
  24. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016 Jan 15; 122(2):304-11.
    View in: PubMed
    Score: 0.020
  25. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.020
  26. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA Oncol. 2015 Jun; 1(3):306-13.
    View in: PubMed
    Score: 0.019
  27. Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst. 2013 Sep 18; 105(18):1365-72.
    View in: PubMed
    Score: 0.017
  28. Computerized analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital mammograms: robustness study with two high-risk datasets. J Digit Imaging. 2012 Oct; 25(5):591-8.
    View in: PubMed
    Score: 0.016
  29. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012 Apr 20; 30(12):1321-8.
    View in: PubMed
    Score: 0.015
  30. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011 Apr 26; 104(9):1384-92.
    View in: PubMed
    Score: 0.014
  31. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010 Dec 01; 70(23):9742-54.
    View in: PubMed
    Score: 0.014
  32. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010 Nov; 124(1):195-203.
    View in: PubMed
    Score: 0.013
  33. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.
    View in: PubMed
    Score: 0.011
  34. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006 May 01; 118(9):2281-4.
    View in: PubMed
    Score: 0.010
  35. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 2006; 8(2):R23.
    View in: PubMed
    Score: 0.010
  36. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res. 2006; 8(2):R15.
    View in: PubMed
    Score: 0.010
  37. Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol. 2005 Jul; 12(7):863-73.
    View in: PubMed
    Score: 0.010
  38. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15; 22(6):1055-62.
    View in: PubMed
    Score: 0.009
  39. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2002 Dec 04; 94(23):1773-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.